Matches in SemOpenAlex for { <https://semopenalex.org/work/W1732278986> ?p ?o ?g. }
- W1732278986 abstract "BackgroundDeep vein thrombosis (DVT) is a condition in which a clot forms in the deep veins, most commonly of the leg. It occurs in approximately 1 in 1,000 people. If left untreated, the clot can travel up to the lungs and cause a potentially life-threatening pulmonary embolism (PE). Previously, a DVT was treated with the anticoagulants heparin and vitamin K antagonists. However, two forms of novel oral anticoagulants (NOACs) have been developed: oral direct thrombin inhibitors (DTI) and oral factor Xa inhibitors. The new drugs have characteristics that may be favourable over conventional treatment, including oral administration, a predictable effect, lack of frequent monitoring or re-dosing and few known drug interactions. To date, no Cochrane review has measured the effectiveness and safety of these drugs in the treatment of DVT.ObjectivesTo assess the effectiveness of oral DTIs and oral factor Xa inhibitors for the treatment of DVT.Search methodsThe Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched January 2015) and the Cochrane Register of Studies (last searched January 2015). We searched clinical trials databases for details of ongoing or unpublished studies and the reference lists of relevant articles retrieved by electronic searches for additional citations.Selection criteriaWe included randomised controlled trials in which people with a DVT confirmed by standard imaging techniques, were allocated to receive an oral DTI or an oral factor Xa inhibitor for the treatment of DVT.Data collection and analysisTwo review authors (LR, JM) independently extracted the data and assessed the risk of bias in the trials. Any disagreements were resolved by discussion with the third review author (PK). We performed meta-analyses when we considered heterogeneity low. The two primary outcomes were recurrent VTE and PE. Other outcomes included all-cause mortality and major bleeding. We calculated all outcomes using an odds ratio (OR) with a 95% confidence interval (CI).Main resultsWe included 11 randomised controlled trials of 27,945 participants. Three studies tested oral DTIs (two dabigatran and one ximelagatran), while eight tested oral factor Xa inhibitors (four rivaroxaban, two apixaban and two edoxaban). We deemed all included studies to be of high methodological quality and generally low risk of bias. The quality of the evidence was generally graded as high as the outcomes were direct and effect estimates were consistent and precise, as reflected in the narrow CIs around the ORs. Meta-analysis of three studies (7596 participants) comparing oral DTIs with standard anticoagulation groups showed no difference in the rate of recurrent VTE (OR 1.09; 95% CI 0.80 to 1.49), recurrent DVT (OR 1.08; 95% CI 0.74 to 1.58), fatal PE (OR 1.00; 95% CI 0.27 to 3.70), non-fatal PE (OR 1.12; 95% CI 0.66 to 1.90) or all-cause mortality ((OR 0.84, 95% CI 0.62 to 1.15). However, oral DTIs were associated with reduced bleeding (OR 0.68; 95% CI 0.47 to 0.98). Meta-analysis of eight studies (16,356 participants) comparing oral factor Xa inhibitors with standard anticoagulation demonstrated a similar rate of recurrent VTE between the two treatments (OR 0.89; 95% CI 0.73 to 1.07). Oral factor Xa inhibitors were associated with a lower rate of recurrent DVT (OR 0.75; 95% CI 0.57 to 0.98). However, this was a weak association, heavily dependent on one study. The rate of fatal (OR 1.20; 95% CI 0.71 to 2.03), non-fatal PE (OR 0.94; 95% CI 0.68 to 1.28) and all-cause mortality (OR 0.84, 95% CI 0.64 to 1.11) was similar between the two treatment groups. Oral factor Xa inhibitors were also associated with reduced bleeding (OR 0.57; 95% CI 0.43 to 0.76). None of the included studies measured post-thrombotic syndrome or health-related quality of life.Authors' conclusionsNOACs such as DTIs and factor Xa inhibitors may be an effective and safe alternative to conventional anticoagulation treatment for acute DVT." @default.
- W1732278986 created "2016-06-24" @default.
- W1732278986 creator A5014944295 @default.
- W1732278986 creator A5050593836 @default.
- W1732278986 creator A5064956832 @default.
- W1732278986 date "2015-06-30" @default.
- W1732278986 modified "2023-10-18" @default.
- W1732278986 title "Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis" @default.
- W1732278986 cites W1482291463 @default.
- W1732278986 cites W1982243812 @default.
- W1732278986 cites W1983727955 @default.
- W1732278986 cites W1998354077 @default.
- W1732278986 cites W2000438765 @default.
- W1732278986 cites W2007680892 @default.
- W1732278986 cites W2010386763 @default.
- W1732278986 cites W2017465843 @default.
- W1732278986 cites W2021678294 @default.
- W1732278986 cites W2024232617 @default.
- W1732278986 cites W2028762958 @default.
- W1732278986 cites W2032267975 @default.
- W1732278986 cites W2039761330 @default.
- W1732278986 cites W2050992159 @default.
- W1732278986 cites W2064696767 @default.
- W1732278986 cites W2067666141 @default.
- W1732278986 cites W2070676143 @default.
- W1732278986 cites W2071869524 @default.
- W1732278986 cites W2073637661 @default.
- W1732278986 cites W2074708727 @default.
- W1732278986 cites W2075352627 @default.
- W1732278986 cites W2075359369 @default.
- W1732278986 cites W2076784235 @default.
- W1732278986 cites W2087552595 @default.
- W1732278986 cites W2089621382 @default.
- W1732278986 cites W2098837786 @default.
- W1732278986 cites W2104841305 @default.
- W1732278986 cites W2112378432 @default.
- W1732278986 cites W2113561246 @default.
- W1732278986 cites W2115787552 @default.
- W1732278986 cites W2115841978 @default.
- W1732278986 cites W2116205803 @default.
- W1732278986 cites W2117662968 @default.
- W1732278986 cites W2118092611 @default.
- W1732278986 cites W2120439011 @default.
- W1732278986 cites W2129225854 @default.
- W1732278986 cites W2130199362 @default.
- W1732278986 cites W2131099415 @default.
- W1732278986 cites W2134430286 @default.
- W1732278986 cites W2135918458 @default.
- W1732278986 cites W2136489990 @default.
- W1732278986 cites W2137914777 @default.
- W1732278986 cites W2139511461 @default.
- W1732278986 cites W2139785591 @default.
- W1732278986 cites W2160625453 @default.
- W1732278986 cites W2166402206 @default.
- W1732278986 cites W2167728254 @default.
- W1732278986 cites W2168248028 @default.
- W1732278986 cites W2168557505 @default.
- W1732278986 cites W2461724753 @default.
- W1732278986 cites W2567073322 @default.
- W1732278986 cites W2592970357 @default.
- W1732278986 cites W2980310908 @default.
- W1732278986 cites W2989714602 @default.
- W1732278986 cites W4245399656 @default.
- W1732278986 cites W4245765453 @default.
- W1732278986 cites W4254940505 @default.
- W1732278986 doi "https://doi.org/10.1002/14651858.cd010956.pub2" @default.
- W1732278986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26123214" @default.
- W1732278986 hasPublicationYear "2015" @default.
- W1732278986 type Work @default.
- W1732278986 sameAs 1732278986 @default.
- W1732278986 citedByCount "44" @default.
- W1732278986 countsByYear W17322789862015 @default.
- W1732278986 countsByYear W17322789862016 @default.
- W1732278986 countsByYear W17322789862017 @default.
- W1732278986 countsByYear W17322789862018 @default.
- W1732278986 countsByYear W17322789862019 @default.
- W1732278986 countsByYear W17322789862020 @default.
- W1732278986 countsByYear W17322789862021 @default.
- W1732278986 countsByYear W17322789862022 @default.
- W1732278986 countsByYear W17322789862023 @default.
- W1732278986 crossrefType "journal-article" @default.
- W1732278986 hasAuthorship W1732278986A5014944295 @default.
- W1732278986 hasAuthorship W1732278986A5050593836 @default.
- W1732278986 hasAuthorship W1732278986A5064956832 @default.
- W1732278986 hasConcept C126322002 @default.
- W1732278986 hasConcept C2777292125 @default.
- W1732278986 hasConcept C2778959117 @default.
- W1732278986 hasConcept C2780868729 @default.
- W1732278986 hasConcept C57002609 @default.
- W1732278986 hasConcept C71924100 @default.
- W1732278986 hasConcept C89560881 @default.
- W1732278986 hasConcept C98274493 @default.
- W1732278986 hasConceptScore W1732278986C126322002 @default.
- W1732278986 hasConceptScore W1732278986C2777292125 @default.
- W1732278986 hasConceptScore W1732278986C2778959117 @default.
- W1732278986 hasConceptScore W1732278986C2780868729 @default.
- W1732278986 hasConceptScore W1732278986C57002609 @default.
- W1732278986 hasConceptScore W1732278986C71924100 @default.
- W1732278986 hasConceptScore W1732278986C89560881 @default.
- W1732278986 hasConceptScore W1732278986C98274493 @default.